A randomized phase II open-label study (Table 1, NCT03939689) is investigating a radioconjugate 131I-1095, for delivering iodine cytotoxicity selectively to the PSMA-expressing prostate cancer cells, in combination with enzalutamide in patients with mCRPC. The gene discussed is FOLH1; the disease is prostate cancer.